GSK2982772 is primarily investigated for its potential therapeutic applications in treating inflammatory diseases. It functions as a selective inhibitor of RIP1 kinase, which plays a critical role in regulating inflammation and cell death pathways. This makes it a promising candidate for conditions such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease, where excessive inflammation is a key factor. Clinical trials have explored its efficacy and safety in managing these chronic inflammatory disorders, aiming to provide a targeted treatment option with fewer side effects compared to traditional anti-inflammatory drugs. Additionally, its mechanism of action suggests potential utility in other diseases involving dysregulated inflammation or cell death, such as neurodegenerative disorders or certain cancers, though further research is needed to confirm these applications.